Original ArticlesPharmacotherapies for Posttraumatic Stress Disorder A Meta-AnalysisGu, Wenjie MS; Wang, Chao MS; Li, Zuofeng PhD; Wang, Zhen MD, PhD; Zhang, Xiaoyan PhDAuthor Information *School of Life Sciences and Technology, Tongji University; and †Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China. Send reprint requests to Xiaoyan Zhang, PhD, School of Life Sciences and Technology, Tongji University, 1239 Siping Rd, Shanghai, PR China 200092. E-mail: [email protected]; [email protected]; and Zhen Wang, MD, PhD, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 Wan Ping Nan Rd, Shanghai, PR China 200030. E-mail: [email protected]; [email protected]. The Journal of Nervous and Mental Disease: May 2016 - Volume 204 - Issue 5 - p 331-338 doi: 10.1097/NMD.0000000000000478 Buy Metrics Abstract The purpose of this study was to assess the acceptability and efficacy of all types of pharmacotherapeutic agents in reducing the symptoms of posttraumatic stress disorder (PTSD). In this systematic meta-analysis, the dropout and response rates of various pharmacotherapy and placebo treatments reported by randomized clinical trials were compared. A total of 34 reports that described the acceptability and efficacy of PTSD pharmacotherapies were retrieved and analyzed. Of them, 30 trials examined the dropout rate as an index of acceptability and revealed the superiority of the PTSD pharmacotherapy to placebos (odds ratio, 0.75; 95% confidence interval, 0.66–0.86; n = 4313). The response rate was determined in 20 trials as an index of efficacy, showing that the PTSD pharmacotherapies were superior to the placebos (odds ratio, 1.47; 95% confidence interval, 1.34–1.62; n = 2166). Pharmacotherapy is an important component of the care of patients with PTSD. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.